NCT03985969View on ClinicalTrials.gov

Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 23, 2019

Primary Completion Date

March 15, 2020

Study Completion Date

March 31, 2020

Conditions
Drug-drug Interaction
Interventions
DRUG

elafibranor

Elafibranor 120mg is a coated tablet for oral administration

DRUG

CHRONO-INDOCID

CHRONO-INDOCID 75mg is a capsule for bis in die (bid) oral administration

Trial Locations (1)

38610

Eurofins Optimed Clinical Pharmacology Unit, Gières

Sponsors

Lead Sponsor

Genfit
All Listed Sponsors
lead

Genfit

INDUSTRY

NCT03985969 - Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin | Biotech Hunter | Biotech Hunter